Abstract: Described herein are methods of treating cancer in a subject in need thereof comprising administering to the subject a pharmaceutical composition comprising 1-(4-(benzylamino)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-2-yl)-2-methyl-1H-indole-4-carboxamide, or a pharmaceutically acceptable salt thereof, whereby the subject experiences a therapeutic response.

Abstract: Integrated software systems and methods that can control the design, emulation, testing and production activities of a conveyor based system. In embodiments, the control system implements an object-oriented like environment into a PLC (Programmable Logic Controller) system and uses its software to define and control the operation of the PLC dynamically from a computer. In other embodiments, a hot backup method allows the conveyor system to continue to function on failure of one or more PLCs.

Abstract: Integrated software systems and methods that can control the design, emulation, testing and production activities of a conveyor based system. In embodiments, the control system implements an object-oriented like environment into a PLC (Programmable Logic Controller) system and uses its software to define and control the operation of the PLC dynamically from a computer. In other embodiments, a hot backup method allows the conveyor system to continue to function on failure of one or more PLCs.

Abstract: Methods and systems for supporting the alternate routing of calls between endpoints, such as session initiation protocol (SIP) endpoints, are provided. An inner gateway alternate route (IGAR) application is invoked when the primary, Internet protocol, communication network is overloaded or otherwise unable to handle a call. The IGAR application assigns incoming and outgoing trunks, and serves as a contact point for session managers in routing the trunk call.

Abstract: Methods and systems for supporting the alternate routing of calls between endpoints, such as session initiation protocol (SIP) endpoints, are provided. An inner gateway alternate route (IGAR) application is invoked when the primary, Internet protocol, communication network is overloaded or otherwise unable to handle a call. The IGAR application assigns incoming and outgoing trunks, and serves as a contact point for session managers in routing the trunk call.

Abstract: The present invention relates to the discovery in eukaryotic cells, particularly human cells, of novel protein-protein interactions between certain cellular proteins, referred to herein as “E6AP-binding proteins” or “E6AP-BPs”, and the cellular protein E6AP, the latter of which is a component of a ubiquitin-ligase (E3) enzyme. The association of E6AP and the subject E6AP-binding proteins implicates the E6AP-binding proteins in a number of basic cellular functions, such as regulation of gene expression, regulation of the cell-cycle, modification of cell surface receptors, biogenesis of ribosomes, and DNA repair. One of the E6AP-binding proteins shares certain homology with the papillomavirus E6 protein, which also binds E6AP.

Abstract: A pill dispensing cap for a bottle has an inner sleeve with a divider panel and a first base panel rotatable within an outer sleeve having a second base panel. First and second window openings are defined in the first and second base panels. A plate moveable across and within the two sleeves defines a third window opening and a fourth window opening is defined in the divider panel. The plate can be held in an initial position wherein the first and second windows are aligned, whilst the third and fourth windows are not aligned. The outer sleeve is rotatable to a condition wherein the first and second windows are not aligned and the plate can then be slid across to a condition wherein the third and fourth windows are aligned to allow pills in a bottle to enter the inner sleeve.

Abstract: A pill dispensing cap for a bottle has an inner sleeve with a divider panel and a first base panel rotatable within an outer sleeve having a second base panel. First and second window openings are defined in the first and second base panels. A plate moveable across and within the two sleeves defines a third window opening and a fourth window opening is defined in the divider panel. The plate can be held in an initial position wherein the first and second windows are aligned, whilst the third and fourth windows are not aligned. The outer sleeve is rotatable to a condition wherein the first and second windows are not aligned and the plate can then be slid across to a condition wherein the third and fourth windows are aligned to allow pills in a bottle to enter the inner sleeve.

Abstract: The present invention relates to the isolation of a new class of ubiquitin ligases involved in protein degradation in vertebrate organisms, such as protein degradation of cell cycle regulatory proteins. Accordingly, the invention provides nucleic acids and the proteins encoded by said nucleic acids which play a role in the ubiquitinylation and subsequent degradation of substrate proteins and in regulating cell proliferation, cell differentiation, and cell survival.

Abstract: Provided are methods for substantially removing organic substances from an aqueous solution, wherein the aqueous solution is contacted with a synthetic hydrated calcium silicate. Components that can be removed from aqueous solution include bacterial, plant, algal and fungal components. Exemplary components include endotoxins. The aqueous solution comprises, for example, water, a chemically buffered solution, a pharmaceutical solution, a solution comprising a nutritional supplement, a culture medium, or a growth medium. Other examples include pharmaceutical compendial water and non-compendial water. In one embodiment of the method, the pH of the aqueous solution is maintained at a selected pH to promote the separation, for example, about pH 5.5 to 9.5, or, e.g., about pH 5.5 to 7.5.

Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.

Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of I.kappa.B and other I.kappa.B-related polypeptides.

Abstract: The present invention concerns a novel human ubiquitin-conjugating enzyme which is implicated in the ubiquitin-mediated inactivation of cell-cycle regulatory proteins, partucularly p53. The present invention makes available diagnostic and therapeutic assays and reagents for detecting and treating transformed cells, such as may be useful in the detection of cancer. The present invention also provides reagents for altering the normal regulation cell proliferation in untransformed cells, such as by upregulating certain cell-cycle checkpoints, e.g. to protect normal cells against DNA damaging reagents.

Abstract: The present invention relates to drug screening assays which provide a systematic and practical approach for the identification of candidate agents able to inhibit ubiquitin-mediated degradation of a cell-cycle regulatory protein, such as p53, p27, myc, fos, MAT.alpha.2, or cyclins. The invention further relates to novel ubiquitin-conjugating enzymes, and uses related thereto.

Abstract: The present invention relates to the discovery that antisense nucleic acids complimentary to an E6AP gene can be used to regulate cellular p53 levels. In general the invention features E6AP antisense constructs which, by inhibiting E6AP activity, can modulate cellular p53 levels in both p53+ transformed cells and in normal cells. The invention also provides methods for treating papillomavirus (PV) induced condition, methods for regulating cellular p53 levels and methods for regulating cellular proliferation.

Abstract: The present invention concerns three ubiquitin-conjugating enzymes.